China’s National Medical Products Administration granted clinical trial clearance to CSPC Pharmaceutical Group for JMT-206, an investigational agent for weight management in people with obesity or overweight plus comorbidity. The approval allows CSPC to begin clinical development of the candidate in China. The clearance marks a near-term regulatory milestone for CSPC as Chinese regulators expand scrutiny of obesity therapeutics. Companies developing weight-management drugs are watching China’s pathway closely because of the large patient pool and potential commercial scale. CSPC will now initiate clinical operations and regulatory reporting consistent with NMPA requirements. Investors and competitors will monitor early safety and pharmacodynamic readouts; the candidate’s differentiation versus global GLP-1 and multi-agonist programs will determine its strategic value in a crowded obesity market.